Long-Term Benefits and Safety of Statins in Patients with Kidney Failure

医学 内科学 危险系数 他汀类 肾脏疾病 不利影响 人口 心力衰竭 心肌梗塞 冲程(发动机) 置信区间 环境卫生 机械工程 工程类
作者
Franco Wing Tak Cheng,Wanchun Xu,Sydney Tang,Eric Yuk Fai Wan
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:36 (5): 882-889 被引量:5
标识
DOI:10.1681/asn.0000000554
摘要

Key Points Patients with kidney failure are at a higher risk of cardiovascular diseases, but the evidence for statin therapy remains inconclusive. The long-term benefits and risks of statin therapy in patients with kidney failure were analyzed using public electronic health records in Hong Kong. Statin therapy was associated with a lower risk of major cardiovascular diseases and all-cause mortality without a higher risk of major adverse events. Background Patients with kidney failure are at elevated risk of cardiovascular diseases. Although statins are commonly used to mitigate cardiovascular risk among the population with high risk, the evidence for initiating statin therapy among patients with kidney failure remains inconclusive. This study aimed to investigate the long-term benefits and risks associated with statin therapy in patients with kidney failure. Methods Using territory-wide public electronic health records in Hong Kong, 3019 statin-eligible individuals with kidney failure and elevated LDL cholesterol ≥100 mg/dl from January 2008 to December 2015 were included for analysis. The framework of target trial emulation was adopted to investigate the risk of the major cardiovascular diseases ( i.e ., a composite of myocardial infarction, heart failure, and stroke), all-cause mortality, and major adverse events ( i.e ., myopathies and liver dysfunction) between statin initiators and statin noninitiators. The pooled logistic model was used to obtain the hazard ratio for the outcomes of interest in both intention-to-treat (ITT) analysis and per-protocol (PP) analysis. Results Significant risk reduction associated with statin therapy (hazard ratio [95% confidence interval]) was observed for major cardiovascular diseases (ITT: 0.78 [0.62 to 0.98]; PP: 0.66 [0.50 to 0.87]) and all-cause mortality (ITT: 0.80 [0.68 to 0.95]; PP: 0.60 [0.48 to 0.76]). The standardized 5- and 10-year absolute risk reduction in PP analysis was 7% (3% to 11%) and 11% (4% to 18%), respectively. No significant risks for the major adverse events were observed. Conclusions Statin therapy was associated with lower risks of cardiovascular diseases and all-cause mortality in patients with kidney failure without a higher risk of major adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI6.2的应助被闯天涯采纳,获得10
1秒前
温柔发卡完成签到,获得积分10
3秒前
3秒前
3秒前
科研通AI6.3的应助被壮观雁易采纳,获得10
4秒前
4秒前
4秒前
xieburou完成签到,获得积分10
5秒前
5秒前
生性不爱说话完成签到,获得积分10
6秒前
JamesPei的应助被霁月采纳,获得10
6秒前
852的应助被霁月采纳,获得10
6秒前
ding的应助被霁月采纳,获得10
7秒前
orixero的应助被霁月采纳,获得10
7秒前
7秒前
LL发布了新的文献求助10
8秒前
葱葱完成签到,获得积分10
8秒前
8秒前
聪明的松糕完成签到,获得积分10
8秒前
火山蜗牛完成签到,获得积分10
9秒前
FZ发布了新的文献求助10
9秒前
10秒前
一米阳光完成签到,获得积分10
10秒前
11秒前
小蘑菇的应助被劳小呆采纳,获得10
11秒前
ajing发布了新的文献求助20
12秒前
12秒前
13秒前
科研通AI6.2的应助被XZM采纳,获得10
13秒前
13秒前
sing完成签到 ,获得积分10
14秒前
14秒前
Mortal完成签到 ,获得积分10
15秒前
15秒前
纯真正豪发布了新的文献求助10
17秒前
酷波er的应助被JXY189采纳,获得10
17秒前
17秒前
香蕉觅云的应助被长庚采纳,获得10
17秒前
研友_ngqgY8完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500